Sinovac's COVID-19 vaccine induces quick immune response: study
Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday (November 18). Bryan Wood reports.
UP NEXT
UP NEXT
-
Exclusive: International COVID-19 vaccine poll shows higher mistrust of Russia, China shots
Reuters
-
WHO team arrives in China's Wuhan to investigate COVID-19 origins
Reuters
-
COVID-19 infection gives some immunity, but virus can still be spread, study finds
Reuters
-
Second year of pandemic 'could even be tougher': WHO's Ryan
Reuters
-
Indonesia launches vaccination drive as COVID-19 deaths hit record
Reuters
-
China sees growing COVID-19 threat as more cities locked down
Reuters
-
U.S. to require negative COVID-19 tests for arriving international air passengers
Reuters
-
EU wraps preliminary talks to buy 60 million Valneva COVID vaccines
Reuters
-
Gorillas at San Diego Zoo Safari Park diagnosed with COVID-19
Reuters
-
Two gorillas at San Diego Zoo test positive for COVID-19
Reuters
-
BioNTech lifts 2021 COVID-19 vaccine output target to 2 billion doses
Reuters
-
UK steps up vaccinations as COVID surges, worst weeks still to come
Reuters
-
Britain approves Moderna's COVID-19 vaccine, eyes spring rollout
Reuters
-
EU says it has secured nearly half of Pfizer's 2021 global output of COVID-19 shots
Reuters
-
Amid COVID-19 surge, S.Africa aims to vaccinate for herd immunity
Reuters
-
Moderna CEO says vaccine likely to protect for 'couple of years'
Reuters